SEC Form 4 · accession 0001209191-15-002172

· CELG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 2, 2015

Accepted (ET)

Jan 6, 2015 · 4:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000816284

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jan 2, 2015	M	45,536	$16.2125	A	45,536	I	By family trust
Common Stock^F2,F1	Jan 2, 2015	S	45,536	$113.4736	D	0	I	By family trust
Common Stock	holding	—	—		—	79,508	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4,F1,F3	$16.2125	Jan 2, 2015	M	45,536	D	—	Dec 29, 2015	Common Stock	45,536	0	I

F1The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F2The price reported in Column 4 is a weighted average price. These shares were sold by two family trusts (the trustee of which is Dr. Kaplan's brother-in-law and the beneficiaries of which are Dr. Kaplan's immediate family members) pursuant to Rule 10b5-1 plans in multiple transactions at prices ranging from $112.65 to $114.35, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F3The option was fully exercisable.
F4The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.